Table of Contents Show
The Indian beauty and personal care industry continues to witness a paradigm shift toward science driven solutions, with Be Clinical emerging as a notable player in this transformation. The evidence led skincare brand has recently announced the successful closure of its Rs 6 crore seed funding round, spearheaded by V3 Ventures, marking a significant milestone in its journey to redefine anti aging skincare for Indian consumers.
Strategic Investment and Investor Confidence
The funding round demonstrates strong institutional backing, with Titan Capital – founded by industry veterans Kunal Bahl and Rohit Bansal reinforcing their commitment by participating once again. Notably, the company had previously raised Rs 2 crore within the same seed round, led by Titan Capital with participation from P-TAL founder Aditya Agarwal. The current raise brings the total seed funding to Rs 6 crore, positioning the startup for accelerated growth in a competitive marketplace.
Addressing a Critical Market Gap
Founded by Hemangi Dhir in May 2025, Be Clinical has distinguished itself through a rigorous, research oriented approach to skincare development. The brand specifically addresses anti aging concerns through clinically validated formulations designed for Indian skin types and environmental conditions. This localized focus sets it apart in a market often dominated by products developed for Western demographics.
The company’s commitment to transparency and scientific validation has resonated strongly with consumers. Within approximately eight months of operations, Be Clinical has successfully served over 25,000 customers, indicating robust market acceptance and consumer trust in its evidence based methodology.
Strategic Deployment of Capital
The freshly raised capital will be channeled into three primary areas. First, the company plans to enhance its research and development capabilities to refine existing product formulations and develop new solutions targeting specific aging related concerns across facial, body, and scalp care. Second, comprehensive clinical testing protocols will be implemented to maintain the brand’s commitment to evidence based efficacy. Third, manufacturing infrastructure will be expanded with advanced machinery to increase production capacity while maintaining stringent quality control standards.
Industry Perspective and Future Outlook
V3 Ventures’ co-founder Arjun Vaidya highlighted the evolving consumer landscape, noting that today’s beauty consumers are increasingly knowledgeable and specific in their requirements. The anti aging segment, which begins attracting consumer attention from the mid twenties onward, represents a substantial untapped opportunity in the Indian market.
As Be Clinical scales its operations with this capital infusion, the company’s emphasis on in house manufacturing capabilities and dermatologist approved formulations positions it favorably to capture growing demand for authentic, clinically proven skincare solutions in India’s burgeoning beauty sector.
Also Read: GOAT Life Secures ₹1.6 Crore in Pre-Seed Extension Round Led by D2C Insider Super Angels
